Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
PharmacoEconomics & Outcomes News 591 - 14 Nov 2009 ■ The cost utility of adjuvant trastuzumab therapy for breast cancer appears more favourable in a Canadian population- based cohort than has ...
. The research aims to evaluate the cost -effectiveness of one-year adjuvant trastuzumab therapy for early-stage breast cancer patients with human epidermal growth receptor 2 (HER2+) from a societal ...
al. Trastuzumab in adjuvant breast cancer therapy . A model based cost -effectiveness analysis Acta Oncol 2007 ; 46 : 153 – 164 Google Scholar Crossref Search ADS PubMed WorldCat 10 Tan-Chiu E , Yothers ...
-positive breast cancer . We investigated the cost -effectiveness of this regimen. Methods A Markov- based microsimulation model with six health states is used to simulate four adjuvant therapy options for women ...
cancer who received adjuvant trastuzumab emtansine (TDM-1). Therefore, we sought to determine the optimal chemotherapy/anti-HER2 treatment strategy. Methods We created a decision-analytic model ...
group compared with the observation group. Breast Cancer Res Treat (2008) 109:559–566 DOI 10.1007/s10549-007-9679-4 EPIDEMIOLOGY The model - based cost -effectiveness analysis of 1-year adjuvant trastuzumab ...
breast cancer and to evaluate the quality of reporting the favorable cost -effectiveness ratios.Data Sources:The terms trastuzumab adjuvant therapy , cost -effectiveness, quality-adjusted, QALY, and early ...
Purpose: One-year adjuvant trastuzumab (AT) therapy , with or without anthracyclines, increases disease-free and overall survival in early-stage HER2/neu-positive breast cancer . We sought to evaluate ...
an economic evaluation to assess the cost -effectiveness and budget impact of adjuvant trastuzumab therapy for HER2-positive EBC in the Philippines, using healthcare system and societal perspectives, in aid ...
this real-world study, 1-year adjuvant trastuzumab treatment is likely to be a cost -effective therapy for patients with HER-2 positive breast cancer at the willingness-to-pay threshold of 3-times GDP per ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!